Cellares
South San Francisco, CA
Platform Provider
Program data pending ClinicalTrials.gov matching
· Last scored 2026-10-29
59.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (20)
○ EMA GMP
○ MHRA GMP
Quick Facts: Cellares
- Signal Score
- 59.0/100 (as of 2026-10-29)
- Quality Compliance
- Assessment pending
- Headquarters
- South San Francisco, CA
- Modalities
- CAR-T, Cell Therapy
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Cellares
Industry 4.0 IDMO model. Cell Shuttle.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesCAR-T, Cell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
58.0
1 manufacturing site: South San Francisco, CA
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100
Sites: South San Francisco, CA
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
StatusAvailable
1 manufacturing site: South San Francisco, CA
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100
Sites: South San Francisco, CA
Press Signals20 articles (not scored)
1 manufacturing site: South San Francisco, CA
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100
Hiring Activity 1 open role Beta
From public job postings on Cellares' careers board, as of Nov 20, 2026. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
1
open role
1
in manufacturing, quality, PD/MSAT, engineering or regulatory (100%)
Trend from Nov 25, 2026
Tracking started Oct 26, 2026. 30-day change shows after 30 days, 90-day after Jan 24, 2027.
Since Nov 19, 2026: 0 new postings, 0 taken down.
By function
By site
South San Francisco, CA
profile site
· 1 eng. 1
· 1 eng. 1
Latest postings
Senior Automation Engineer
Engineering & facilities · South San Francisco, CA · posted Oct 6, 2026
Coverage: counted from Cellares' own careers board.
Function groups come mainly from job titles (about 84% match a hand check), and modality words from titles only, so both are approximate.
Source:
jobs.lever.co
· Checked Nov 20, 2026 · Tracking since Oct 26, 2026
Company Signals 20 articles
Company announcements, not verified evidence. They do not change any score.
Cabaletta, Cellares Sign Manufacturing Deal for Rese-Cel Supply - MyChesCo
Cabaletta, Cellares Sign Manufacturing Deal for Rese-Cel Supply MyChesCo
Cellares, Cabaletta Bio sign 10-year CAR-T therapy commercial supply deal - megaproject.com
Cellares, Cabaletta Bio sign 10-year CAR-T therapy commercial supply deal megaproject.com
Cellares to manufacture Cabaletta CAR-T under 10-year deal - NJBIZ
Cellares to manufacture Cabaletta CAR-T under 10-year deal NJBIZ
Cabaletta Bio signs 10-year manufacturing deal with Cellares - Investing.com
Cabaletta Bio signs 10-year manufacturing deal with Cellares Investing.com
Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel - Business Wire
Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel Business Wire
Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel - The Manila Times
Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel The Manila Times
Cellares, Cabaletta Bio sign 10-year manufacturing deal for rese-cel - Investing.com Canada
Cellares, Cabaletta Bio sign 10-year manufacturing deal for rese-cel Investing.com Canada
Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel - BioSpace
Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel BioSpace
Cellares, Cabaletta Bio Ink 10-Year Commercial Supply Pact for Investigational CAR-T Therapy - Contract Pharma
Cellares, Cabaletta Bio Ink 10-Year Commercial Supply Pact for Investigational CAR-T Therapy Contract Pharma
Cellares, Cabaletta Bio sign 10-year manufacturing deal for rese-cel - Investing.com UK
Cellares, Cabaletta Bio sign 10-year manufacturing deal for rese-cel Investing.com UK
Cabaletta Bio signs 10-year manufacturing deal with Cellares - Investing.com UK
Cabaletta Bio signs 10-year manufacturing deal with Cellares Investing.com UK
Cellares, Cabaletta Bio sign 10-year manufacturing deal for rese-cel - Investing.com
Cellares, Cabaletta Bio sign 10-year manufacturing deal for rese-cel Investing.com
Cabaletta Bio signs 10-year manufacturing deal with Cellares By Investing.com - Investing.com India
Cabaletta Bio signs 10-year manufacturing deal with Cellares By Investing.com Investing.com India
Cellares, Cabaletta Bio sign 10-year manufacturing deal for rese-cel - Investing.com Australia
Cellares, Cabaletta Bio sign 10-year manufacturing deal for rese-cel Investing.com Australia
Cabaletta Bio signs 10-year manufacturing deal with Cellares By Investing.com - Investing.com India
Cabaletta Bio signs 10-year manufacturing deal with Cellares By Investing.com Investing.com India
Cellares, Cabaletta Bio sign 10-year manufacturing deal for rese-cel - Investing.com UK
Cellares, Cabaletta Bio sign 10-year manufacturing deal for rese-cel Investing.com UK
Cellares and City of Hope to Automate Manufacturing of Solid Tumor CAR T Cell Therapy - The National Law Review
Cellares and City of Hope to Automate Manufacturing of Solid Tumor CAR T Cell Therapy The National Law Review
First Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform - Business Wire
First Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform Business Wire
CAR T Cell Therapy Biomanufactured by Cellares Infused Into First Two Patients - Genetic Engineering and Biotechnology News
CAR T Cell Therapy Biomanufactured by Cellares Infused Into First Two Patients Genetic Engineering and Biotechnology News
Cabaletta Bio Doses First Patients With Rese-cel Manufactured on Cellares' Automated Platform - National Today
Cabaletta Bio Doses First Patients With Rese-cel Manufactured on Cellares' Automated Platform National Today
Frequently Asked Questions About Cellares
What is Cellares's CDMO Signal Score?
Cellares has a Signal Score of 59/100, based on quality, operations, financial stability, and capacity data.
Evaluating Cellares for a manufacturing program?
Use the free AI matchmaker to compare Cellares against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
City of Hope (T Cell Manufacturing)
Duarte, CA
Signal Score: 84.0
CAR-T, Cell Therapy
Poseida Therapeutics (CDMO)
San Diego, CA
Signal Score: 58.7
CAR-T, Cell Therapy, Gene Editing
Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
Signal Score: 87.0
CAR-T, Cell Therapy
Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
Signal Score: 83.1
CAR-T, Cell Therapy
Compare Cellares with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.